Cidara Therapeutics Gross Profit

As of the most recent data (September 2025), CDTX shows a gross profit of $-45M. That compares with $24M in the prior-year period — down 290.9% year over year. That is below the Healthcare sector average of $67B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CDTX's gross profit is now $-45M (was $24M) — a 290.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cidara Therapeutics is outperforming or lagging.

The Healthcare sector average gross profit is about $67B. Cidara Therapeutics is at $-45M, which is lower that average. That is roughly 100.1% below the sector mean. Use the comparison chart on this page to see how CDTX stacks up against individual peers as well.

Tracking CDTX's gross profit over time shows whether Cidara Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-45M That compares with $24M in the prior-year period — down 290.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has Cidara Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $-45M) with ownership activity and broader fundamentals.